drugset / Trial / NCT05646524
Study of Efficacy and Safety of NM8074 in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase II, open-label study designed to evaluate the safety, efficacy, and immunogenicity of NM8074 administered intravenously to adult patients with Paroxysmal Nocturnal Hemoglobinuria (PNH).
Timeline
- Start
- 2026-04
- Primary completion
- 2027-08
- Completion
- 2028-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RUXOPRUBART | Monoclonal antibody | 20 mg/kg | Intravenous |